Biocon will continue to focusing on its product mix, operating leverage, and cost efficiencies while maintaining R&D spends at around 7 per cent of revenue, its MD & CEO Shreehas Tambe said on Thursday
| Photo Credit:
Abhishek Chinnappa
Biocon expects a stronger second half of FY27 as its recent biosimilar launches in the US have begun contributing meaningfully to revenues.“We see a much more exciting second half than the first half,” Shreehas Tambe, the CEO and Managing Director of the company, said during the a post-results press conference in Bengaluru. He pointed to the five recent product launches in the US, including biosimilar aflibercept (Yesafili), denosumab biosimilars Bosaya and Aukelso, and generic liraglutide which could gain from the favourable regulatory changes in the market.The company, which reported a 10 per cent increase in its June quarter consolidated revenue to ₹4,336 crore from the year-ago period, said the momentum from multiple product launches will become more visible over the coming quarters.Tambe said the Yesafili, the biosimilar to Eylea (an eye injection), addresses a market worth roughly $3 billion in the US. While concerns had existed around physician adoption because the therapy is injected into the retina, he said those fears had largely dissipated following successful launches by earlier biosimilar entrants.Customer enquiries and orders, Tambe said, had already begun coming in, while Biocon also enjoys a temporary lead over competitors through its patent settlement agreement, giving it a head start in commercialising the product.Favourable environmentBeyond product launches, the CEO said recent changes in the US regulatory framework could benefit companies with proven capabilities to develop biosimilars. The US regulator’s move away from mandatory phase-3 comparative efficacy trials places greater emphasis on analytical and pharmacokinetic studies, an area where incumbent players such as Biocon already have significant experience.“We have already received waivers for phase-3 studies for products in our pipeline,” he said, adding that the regulatory shift was likely to favour established biosimilar manufacturers over newer entrants.On profitability, Tambe said the company will continue to focus on its product mix, operating leverage, and cost efficiencies while maintaining research and development (R&D) spending at around 7 per cent of revenue. Factors such as tariffs, geopolitical developments, and logistics costs remain external risks that could affect margins, although the company’s overall business strategy remains unchanged, he added.Published on August 6, 2026
